The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ketostix® and Keto-Diastix® Performance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06053593
Recruitment Status : Completed
First Posted : September 25, 2023
Last Update Posted : March 29, 2024
Sponsor:
Information provided by (Responsible Party):
Ascensia Diabetes Care

Brief Summary:
Persons with Diabetes (PWDs), at minimum of (n=120) will successfully collect their urine and test with two Ascensia strip products. The products are: Ketostix and Keto-Diastix.

Condition or disease Intervention/treatment
Urinalysis Device: Testing of self collected urine Device: Labeling Evaluation Device: Urine Control testing

Detailed Description:

Persons with Diabetes (PWDs), at minimum of (n=120) will successfully collect their urine and test with two Ascensia strip products.

  1. Demonstrate that untrained PWDs can successfully read the Instructions for Use and use Ketostix and Keto-Diastix reagent strips for Urinalysis with no training. Urine samples from the PWDs will be collected and then tested by the PWD and will be compared to the reference assay results.
  2. Demonstrate Ease of Use by PWDs with a Labeling Evaluation Survey for Ketostix and Keto-Diastix reagent strips. Participants will respond to a survey using a 5 point Likert scale with 5= Strongly Agree, 4= Agree, 3=Neutral, 2=Disagree, 3=Strongly Disagree.
  3. Demonstrate that persons with diabetes (PWDs) can successfully test urinalysis control solutions.

Layout table for study information
Study Type : Observational
Actual Enrollment : 126 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Ketostix® and Keto-Diastix® Performance Study
Actual Study Start Date : July 24, 2023
Actual Primary Completion Date : November 30, 2023
Actual Study Completion Date : November 30, 2023

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Testing of Ketostix by Persons with Diabetes.
Each PWD will test Ketostix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
Device: Testing of self collected urine
Each PWD will test their self-collected urine.

Device: Labeling Evaluation
Each PWD will complete a labeling evaluation.

Device: Urine Control testing
Each PWD will test four urine control solutions.

Testing of Keto-Diastix by Persons with Diabetes.
Each PWD will test Keto-Diastix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
Device: Testing of self collected urine
Each PWD will test their self-collected urine.

Device: Labeling Evaluation
Each PWD will complete a labeling evaluation.

Device: Urine Control testing
Each PWD will test four urine control solutions.




Primary Outcome Measures :
  1. Testing of self collected urine [ Time Frame: Day 1 ]
    Number of Participants with results from self collected urine that are within one color block of reference analyzer

  2. Labeling evaluation [ Time Frame: Day 1 ]
    Number of Participants with Responses that are a 3,4, or 5 on a 5 point Likert Scale.

  3. Testing of Urine controls [ Time Frame: Day 1 ]
    Number of Participants with Reponses that read within one color block.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Person with Diabetes.
Criteria

Inclusion Criteria:

  • Males and females over 18 years of age.
  • Diagnosed with Diabetes Mellitus (Type 1 or Type 2)
  • Able to speak, read and understand English (subjects must demonstrate ability to read a paragraph from the first page of the package insert to qualify for the study).
  • Willing to complete all study procedures.

Exclusion Criteria:

  • Physical, visual, or neurological impairments that would make the person unable to perform urine collection and testing with the urine strips as determined by the PI.
  • Intake of Vitamin C supplements (multi-vitamins are permitted)
  • Prior experience testing glucose or ketones in urine with Ketostix and Keto-Diastix Reagent strips.
  • Currently taking compounds such as mesna (Mesnex)
  • Currently taking any medications containing azo dyes (e.g., Pyridium, Gantrisin, Gantanol), nitrofurantoin (Macrodantin, Furadantin).
  • Currently taking medications such as levodopa.
  • Working for a medical laboratory, hospital or other clinical setting that involves training in the urinalysis lab or use of urinalysis test strips.
  • Working for a competitive medical device company (Urine Strip manufacturer) or having an immediate family member or living with someone who works for such a company.
  • A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk (reason for exclusion will be clearly documented by investigator or designee on the study form).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06053593


Locations
Layout table for location information
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Ascensia Diabetes Care
Investigators
Layout table for investigator information
Principal Investigator: Robert H Christenson, PhD University of Maryland
Layout table for additonal information
Responsible Party: Ascensia Diabetes Care
ClinicalTrials.gov Identifier: NCT06053593    
Other Study ID Numbers: GCA-PRO-2022-002-01
First Posted: September 25, 2023    Key Record Dates
Last Update Posted: March 29, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes